1. Home
  2. NRGV vs LBRX Comparison

NRGV vs LBRX Comparison

Compare NRGV & LBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Energy Vault Holdings Inc.

NRGV

Energy Vault Holdings Inc.

HOLD

Current Price

$5.30

Market Cap

731.4M

Sector

Miscellaneous

ML Signal

HOLD

LBRX

LB Pharmaceuticals Inc

HOLD

Current Price

$28.63

Market Cap

850.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NRGV
LBRX
Founded
2017
2015
Country
United States
United States
Employees
N/A
27
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Miscellaneous
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
731.4M
850.5M
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
NRGV
LBRX
Price
$5.30
$28.63
Analyst Decision
Strong Sell
Strong Buy
Analyst Count
1
5
Target Price
$2.00
$46.60
AVG Volume (30 Days)
4.7M
127.3K
Earning Date
05-05-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
28.57
N/A
EPS
N/A
N/A
Revenue
$203,671,000.00
N/A
Revenue This Year
$28.93
N/A
Revenue Next Year
$16.69
N/A
P/E Ratio
N/A
N/A
Revenue Growth
340.86
N/A
52 Week Low
$0.70
$13.40
52 Week High
$6.40
$33.47

Technical Indicators

Market Signals
Indicator
NRGV
LBRX
Relative Strength Index (RSI) 57.64 45.74
Support Level $2.95 $22.39
Resistance Level $5.73 $33.47
Average True Range (ATR) 0.55 1.64
MACD -0.05 -0.58
Stochastic Oscillator 56.98 30.06

Price Performance

Historical Comparison
NRGV
LBRX

About NRGV Energy Vault Holdings Inc.

Energy Vault Holdings Inc is a diversified portfolio of energy storage solutions to third parties, including proprietary gravity, battery, and green hydrogen-based technologies, supported by technology-agnostic energy management software and integration capabilities. Geographical presence in the United States, Australia, and other countries. The majority of its revenue comes from Australia.

About LBRX LB Pharmaceuticals Inc

LB Pharmaceuticals Inc is a late-stage biopharmaceutical company developing novel therapies for the treatment of a wide range of neuropsychiatric disorders including schizophrenia, bipolar depression, adjunctive treatment of depressive disorder and other diseases. It is building a pipeline that leverages the broad therapeutic potential of its product candidate, LB-102, which it believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is currently in late-stage clinical development for schizophrenia and bipolar depression. The company operates as a single reportable segment in the development of novel therapies for the treatment of neuropsychiatric diseases, including schizophrenia.

Share on Social Networks: